Evidence map›Paper›PMID 33961152›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations.

Mitsuhiro Nikaido, Nobuyuki Kakiuchi, Shin'ichi Miyamoto, Tomonori Hirano, Yasuhide Takeuchi, Taro Funakoshi, Akira Yokoyama, Tatsuki Ogasawara, Yoshihiro Yamamoto, Atsushi Yamada and 12 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Mapping the genetic landscape of hereditary diffuse-type gastric cancer progression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Helicobacter pylori-naïve status is associated with poor prognosis and aggressive pathological features in undifferentiated-type gastric cancer: a multi-center retrospective cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  7. Transcriptional profiling revealsFrontiers in immunology · 2025
    Article
  8. A mathematical simulation model to determine the optimal endoscopic screening strategy for detection of H. pylori-naïve gastric neoplasms.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. [Clinicopathological features ofBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 2 countries.

Mitsuhiro Nikaido *Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-7675-0495
Nobuyuki Kakiuchi *Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0003-4893-5414
Shin'ichi MiyamotoDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. shmiyamo@kuhp.kyoto-u.ac.jp.ORCID 0000-0003-2298-0970
Tomonori HiranoDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yasuhide TakeuchiDepartment of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Taro FunakoshiDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Akira YokoyamaDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tatsuki OgasawaraDepartment of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshihiro YamamotoDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Atsushi YamadaDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi SetoyamaDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takahiro ShimizuDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yukari KatoDepartment of Gastroenterology and Hepatology, Kansai Electric Power Hospital, Osaka, Japan.
Suguru UoseDepartment of Gastroenterology and Hepatology, Kansai Electric Power Hospital, Osaka, Japan.
Takaki SakuraiDepartment of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Sachiko MinamiguchiDepartment of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-5800-6769
Kazutaka ObamaDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshiharu SakaiDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Manabu MutoDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tsutomu ChibaDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-7778-5374
Hiroshi SenoDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kyoto University · JPKansai Electric Power Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Helicobacter pylori (Hp)-uninfected individuals, diffuse-type gastric cancer (DGC) was reported as the most common type of cancer. However, the carcinogenic mechanism of Hp-uninfected sporadic DGC is largely unknown.

methodsWe performed whole-exome sequencing of Hp-uninfected DGCs and Hp-uninfected normal gastric mucosa. For advanced DGCs, external datasets were also analyzed.

resultsEighteen patients (aged 29-78 years) with DGCs and nine normal subjects (28-77 years) were examined. The mutation burden in intramucosal DGCs (10-66 mutations per exome) from individuals aged 29-73 years was not very different from that in the normal gastric glands, which showed a constant mutation accumulation rate (0.33 mutations/exome/year). Unbiased dN/dS analysis showed that CDH1 somatic mutation was a driver mutation for intramucosal DGC. CDH1 mutation was more frequent in intramucosal DGCs (67%) than in advanced DGCs (27%). In contrast, TP53 mutation was more frequent in advanced DGCs (52%) than in intramucosal DGCs (0%). This discrepancy in mutations suggests that CDH1-mutated intramucosal DGCs make a relatively small contribution to advanced DGC formation. Among the 16 intramucosal DGCs (median size, 6.5 mm), 15 DGCs were pure signet ring cell carcinoma (SRCC) with reduced E-cadherin expression and a low proliferative capacity (median Ki-67 index, 2.4%). Five SRCCs reviewed endoscopically over 2-5 years showed no progression.

conclusionsImpaired E-cadherin function due to CDH1 mutation was considered as an early carcinogenic event of Hp-uninfected intramucosal SRCC. Genetic and clinical analyses suggest that Hp-uninfected intramucosal SRCCs may be less likely to develop into advanced DGCs.

Indexed as

Carcinoma, Signet Ring CellHelicobacter pyloriStomach NeoplasmsAntigens, CDCadherinsHumansMutationAntigens, CDCadherinsCDH1 protein, humanCDH1Helicobacter pyloriSignet ring cell carcinomaStomach neoplasmWhole-exome sequencing

Identifiers

PMID33961152
OpenAlexW3159084288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.